Total amount: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Online ISSN 1827-1758
XVI CONGRESS DELLA SOCIETÀ ITALIANA DI NEFROLOGIA SEZIONE PIEMONTE-VALLE D’AOSTA
Castello di Rivoli, Rivoli (TO) October 10, 1998
Dionisio P., Valenti M., Caramello E., Bergia R., Cravero R., Berto I. M., Agostini B., Monaci G., Bajardi P.
Ospedale degli Infermi - Biella Servizio di Nefrologia e Dialisi
Losartan is the first of a new cathegory of drug that inhibits angiotensin II (ANG II) AT1 receptors antagonists. This drug lowers blood pressure by inhibiting the activity of ANG II and reduces proteinuria and progression of chronic renal failure (CRF). It seems therefore an extremely interesting drug. Aim of this study is to describe 3 cases of acute renal failure (ARF), occurred during therapy with losartan. None of the patients showed renal arteries stenosis or other predisposing factors for the development of ARF. In conclusion, we want pointed out that losartan could affect renal function in a similar way as angiotensin converting enzyme inhibitors (ACEI). We suggested that the use of losartan in risk situations, like old age, preexiting CRF, stenosis of renal arteries, soliary kidney and diuretic therapy, should be carefully monitored as well as that of ACEI.